Advertisement

Topics

PharmaMar USA Company Profile

11:56 EST 17th December 2018 | BioPortfolio

PharmaMar was founded in 1986, as part of the Zeltia group, with the vision of exploiting the great potential of the oceans as a source of novel medicines for improved cancer treatment. PharmaMar headquarters are located in Madrid (Spain) with additional laboratories located in Cambridge (Massachusetts).
PharmaMar has become a leading company in the field of marine anticancer drugs, with six novel molecules in clinical development: Yondelis® in Phase III clinical trials, Aplidin® and Kahalalide F in Phase II, and ES-285, Zalypsis® and PM02734 in Phase I.

At PharmaMar we are very proud of our over 200 highly skilled professionals and experienced management team. We feel we are in an excellent position to achieve the goal of developing and marketing our own oncology products.

Location

320 Putman Av.
Cambridge
Massachussets
02139
United States of America

Contact

Phone: 1 617 868 3797
Fax: 1 617 868 0109
Email: pharmamar@pharmamar.com


News Articles [18 Associated News Articles listed on BioPortfolio]

PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis in the Nordic Countries and Eastern Europe

MADRID, July 27, 2018 /PRNewswire/ -- PharmaMar will receive an up-front payment of 2 million euros This agreement will replace the current agreement between PharmaMar and Swedish Orphan Biovitrum...

PharmaMar and Chugai agree to terms for early termination of the agreement for Zepsyre in Japan

(Pharmamar) On April 27th, 2018 PharmaMar (MSE:PHM) reported to National Securities Market Commission that Chugai Pharmaceutical Co., Ltd. had exercised its right to terminate without cause the Licens...

PharmaMar announces the signature of a Memorandum of Understanding with the Indonesian Oceanographic Research Center to address the fight against cancer

(Pharmamar) Both institutions will combine their efforts, knowledge and resources to promote research into marine biodiversity as a source of novel antitumor compounds.

FDA grants orphan status to PharmaMar's small cell lung cancer drug

The FDA granted orphan drug status to PharmaMar's PM1183, or lurbinectedin, which is being developed as a treatment for patie -More- 

PharmaMar presents at ASCO the ADMYRE study's adjusted overall survival with plitidepsin

(Pharmamar) PharmaMar (MSE:PHM) has presented today how crossover has had an influence on the overall survival of the ADMYRE trial. The impact on overall survival of those patients that relapsed after...

PharmaMar receives Australian approval for Aplidin to treat multiple myeloma

PharmaMar announces that the Australian Regulatory Agency (TGA) has informed STA that Aplidin (plitidepsin) has been approved for the treatment of multiple myeloma in combination with dexamethasone.

PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin With Pint Pharma International

MADRID, June 11, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International, S.A. for the ma...

FDA Grants Orphan Drug Designation to PharmaMar’s Lurbinectedin for Treatment of Small Cell Lung Cancer

PharmaMar (MCE: PHM) announces that lurbinectedin has been granted orphan drug status by the FDA for the treatment of small cell lung cancer. The FDA’s Office of Orphan Drug Products grants orph...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

PharmaMar USA

PharmaMar was founded in 1986, as part of the Zeltia group, with the vision of exploiting the great potential of the oceans as a source of novel medicines for improved cancer treatment. PharmaMar head...

PharmaMar

PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and selling marine-based drugs to treat cancer. Yondelis(R) is Spain's first anti-cancer drug. It ...

Group Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of ...

INMUNAL S.A. - Alcarria, 7 Pol. Ind

Instituto de Inmunología y Alergia, S.A. (INMUNAL, S.A.) es una compañía que viene desarrollando su actividad desde 1.989, en el estudio y elaboración de productos inmunológicos personalizados di...

More Information about "PharmaMar USA" on BioPortfolio

We have published hundreds of PharmaMar USA news stories on BioPortfolio along with dozens of PharmaMar USA Clinical Trials and PubMed Articles about PharmaMar USA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PharmaMar USA Companies in our database. You can also find out about relevant PharmaMar USA Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record